At the news
? BULLISHIMPACT 7/10 8-K filed Nov 6, 2026 at 06:47 ET
Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and GAAP diluted EPS of $0.38 (consensus $-1.25), a significant beat driven by higher COVID vaccine sales in international markets. The company raised its full-year 2026 revenue growth outlook to 15%-25% from up to 10%, improved its year-end cash balance forecast to $8.1B-$8.3B, and highlighted the FDA approval of mFLUSIVA and positive Phase 3 data for intismeran in melanoma.
- Q3 2026 total revenue $1.313B, up 29% YoY from $1.016B
- GAAP diluted EPS $0.38, compared to a loss per share of $(0.51) in Q3 2025
- Net income of $162M, compared to a net loss of $(200M) in Q3 2025
- 2026 revenue growth outlook raised to 15%-25%, exceeding prior expectation of up to 10% growth
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access